# Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

> **NCT03304379** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 1650 (actual)

## Conditions studied

- Osteoarthritis, Knee
- Osteoarthritis, Hip

## Interventions

- **DRUG:** Fasinumab
- **OTHER:** Diclofenac
- **OTHER:** Celecoxib
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT03304379
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-26
- **Primary completion:** 2019-12-13
- **Final completion:** 2020-11-09
- **Target enrollment:** 1650 (ACTUAL)
- **Last updated:** 2023-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03304379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03304379, "Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03304379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*